olfactory receptor family 51 subfamily E member 2Genealiases: HPRAJ · OR51E3P · OR52A2 · PSGR
Q-omics provides the consensus-scored OR51E2 profile across patient tissues and cancer cell-line models. OR51E2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, OR51E2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, OR51E2 RNA expression shows 11,194 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SCLC, KIRC, and TGCT as cancer lineages where OR51E2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR51E2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR51E2 survival associations across molecular data types. OR51E2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR51E2 RNA expression–survival associations across cancer types. High OR51E2 expression shows unfavorable associations in ACC, BRCA and KIRP, but favorable associations in SCLC, KIRC and ESCA. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for OR51E2 RNA expression.
This table summarizes OR51E2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OR51E2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR51E2 shows lower tumor expression in COAD and higher tumor expression in KIRC, BRCA, HNSC, LIHC and LUAD. The KIRC box plot shows higher OR51E2 RNA expression in tumor versus normal tissue (log2 FC = +1.562, t-test p < 0.001).
This table shows molecular features associated with OR51E2 in patient tissues and cancer cell lines. In patient samples, OR51E2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, OR51E2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
